BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang Y, Zheng B, Han Q, Zhang C, Tian Z, Zhang J. Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma. Cancer Biol Ther. 2016;17:449-456. [PMID: 26934469 DOI: 10.1080/15384047.2016.1156257] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Cheng H, Wang S, Huang A, Ma J, Gao D, Li M, Chen H, Guo K. HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma. Cancer Biol Ther 2023;24:1-9. [PMID: 36482717 DOI: 10.1080/15384047.2022.2156242] [Reference Citation Analysis]
2 Srivastava S, Chaudhary N, Dhembla C, Sundd M, Gupta S, Patel AK. STAT3 inhibition mediated upregulation of multiple immune response pathways in dengue infection. Virology 2023;578:81-91. [PMID: 36473280 DOI: 10.1016/j.virol.2022.11.009] [Reference Citation Analysis]
3 Wang X, Hu R, Song Z, Zhao H, Pan Z, Feng Y, Yu Y, Han Q, Zhang J. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity. Cancer Lett 2022;547:215880. [PMID: 35981569 DOI: 10.1016/j.canlet.2022.215880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Boulahtouf Z, Virzì A, Baumert TF, Verrier ER, Lupberger J. Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences. Int J Mol Sci 2022;23:2787. [PMID: 35269929 DOI: 10.3390/ijms23052787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Guo D, Zhang X, Cui H, Yu D, Zhang H, Shi X, Pang C, Li J, Guo W, Zhang S. ACADL Functions as a Tumor Suppressor in Hepatocellular Carcinoma Metastasis by Inhibiting Matrix Metalloproteinase 14. Front Oncol 2022;12:821484. [DOI: 10.3389/fonc.2022.821484] [Reference Citation Analysis]
6 Guo D, Gu Y, Ma D, Liu P, Chen B, Liu Z, Wu P, Liu Q. A novel microRNA miR-MTCO3P38 inhibits malignant progression via STAT3/PTTG1/MYC in hepatocellular carcinoma. Genes & Diseases 2021. [DOI: 10.1016/j.gendis.2021.11.006] [Reference Citation Analysis]
7 Srivastava S, Chaudhary N, Ojha A, Guchhait P, Patel AK. Signal transducer and activator of transcription 3 (STAT3) acts as a proviral factor for dengue virus propagation. Virus Res 2021;300:198436. [PMID: 33901593 DOI: 10.1016/j.virusres.2021.198436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Li Y, Han Q, Zhao H, Guo Q, Zhang J. Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Pharmacol 2020;11:597520. [PMID: 33343368 DOI: 10.3389/fphar.2020.597520] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hu ZG, Zhang S, Chen YB, Cao W, Zhou ZY, Zhang JN, Gao G, He SQ. DTNA promotes HBV-induced hepatocellular carcinoma progression by activating STAT3 and regulating TGFβ1 and P53 signaling. Life Sci 2020;258:118029. [PMID: 32619495 DOI: 10.1016/j.lfs.2020.118029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Turton KL, Meier-Stephenson V, Badmalia MD, Coffin CS, Patel TR. Host Transcription Factors in Hepatitis B Virus RNA Synthesis. Viruses. 2020;12:160. [PMID: 32019103 DOI: 10.3390/v12020160] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
11 Yoo YS, Park YJ, Lee HS, Oanh NTK, Cho MY, Heo J, Lee ES, Cho H, Park YY, Cho H. Mitochondria ubiquitin ligase, MARCH5 resolves hepatitis B virus X protein aggregates in the liver pathogenesis. Cell Death Dis 2019;10:938. [PMID: 31819032 DOI: 10.1038/s41419-019-2175-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
12 Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25(25): 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 54] [Article Influence: 13.5] [Reference Citation Analysis]
13 Juengpanich S, Shi L, Iranmanesh Y, Chen J, Cheng Z, Khoo AK, Pan L, Wang Y, Cai X. The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review. Transl Oncol. 2019;12:1092-1107. [PMID: 31176993 DOI: 10.1016/j.tranon.2019.04.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
14 Zhao Z, Xiong S, Wang R, Li Y, Wang X, Wang Y, Bai S, Chen W, Zhao Y, Cheng B. Peri-tumor fibroblasts promote tumorigenesis and metastasis of hepatocellular carcinoma via Interleukin6/STAT3 signaling pathway. Cancer Manag Res 2019;11:2889-901. [PMID: 31118769 DOI: 10.2147/CMAR.S192263] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
15 Ma H, Yan D, Wang Y, Shi W, Liu T, Zhao C, Huo S, Duan J, Tao J, Zhai M, Luo P, Guo J, Tian L, Mageta L, Jou D, Zhang C, Li C, Lin J, Lv J, Li S, Lin L. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma. Cancer Sci. 2019;110:950-961. [PMID: 30648776 DOI: 10.1111/cas.13940] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
16 Lei H, Wang G, Zhang J, Han Q. Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity. Oncol Rep 2018;40:3447-57. [PMID: 30272318 DOI: 10.3892/or.2018.6740] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
17 Chen QF, Xia JG, Li W, Shen LJ, Huang T, Wu P. Examining the key genes and pathways in hepatocellular carcinoma development from hepatitis B virus‑positive cirrhosis. Mol Med Rep 2018;18:4940-50. [PMID: 30272310 DOI: 10.3892/mmr.2018.9494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
18 Chang Z, Wang Y, Zhou X, Long JE. STAT3 roles in viral infection: antiviral or proviral? Future Virol 2018;13:557-74. [PMID: 32201498 DOI: 10.2217/fvl-2018-0033] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
19 Song J, Zhang X, Ge Q, Yuan C, Chu L, Liang HF, Liao Z, Liu Q, Zhang Z, Zhang B. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. J Cell Biochem 2018;119:8419-31. [PMID: 29904948 DOI: 10.1002/jcb.27050] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
20 Roca Suarez AA, Van Renne N, Baumert TF, Lupberger J. Viral manipulation of STAT3: Evade, exploit, and injure. PLoS Pathog 2018;14:e1006839. [PMID: 29543893 DOI: 10.1371/journal.ppat.1006839] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 9.6] [Reference Citation Analysis]
21 Mui UN, Haley CT, Tyring SK. Viral Oncology: Molecular Biology and Pathogenesis. J Clin Med 2017;6:E111. [PMID: 29186062 DOI: 10.3390/jcm6120111] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 12.2] [Reference Citation Analysis]
22 Jia H, Song Y, Yu J, Zhan P, Rai D, Liang X, Ma C, Liu X. Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. European Journal of Medicinal Chemistry 2017;136:144-53. [DOI: 10.1016/j.ejmech.2017.04.048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
23 Lu R, Zhang YG, Sun J. STAT3 activation in infection and infection-associated cancer. Mol Cell Endocrinol 2017;451:80-7. [PMID: 28223148 DOI: 10.1016/j.mce.2017.02.023] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
24 Jia H, Bai F, Liu N, Liang X, Zhan P, Ma C, Jiang X, Liu X. Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. Eur J Med Chem 2016;123:202-10. [PMID: 27484509 DOI: 10.1016/j.ejmech.2016.07.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]